Business Description
Puma Biotechnology Inc
NAICS : 325412
SIC : 2834
ISIN : US74587V1070
Description
Financial Strength
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.86 | |||||
Equity-to-Asset | 0.23 | |||||
Debt-to-Equity | 2.09 | |||||
Debt-to-EBITDA | 2.35 | |||||
Interest Coverage | 2.5 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | -5.54 | |||||
Beneish M-Score | -2.49 | |||||
WACC vs ROIC |
Growth Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -4.5 | |||||
Future 3-5Y Total Revenue Growth Rate | 116.9 |
Momentum Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 46.12 | |||||
9-Day RSI | 43.6 | |||||
14-Day RSI | 44.53 | |||||
6-1 Month Momentum % | 139.32 | |||||
12-1 Month Momentum % | 115.38 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.57 | |||||
Quick Ratio | 1.5 | |||||
Cash Ratio | 0.97 | |||||
Days Inventory | 33.55 | |||||
Days Sales Outstanding | 55.64 | |||||
Days Payable | 40.5 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -5.9 | |||||
Shareholder Yield % | 1.12 |
Profitability Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 73.4 | |||||
Operating Margin % | 14.12 | |||||
Net Margin % | 9.16 | |||||
FCF Margin % | 6.1 | |||||
ROE % | 63.49 | |||||
ROA % | 10.25 | |||||
ROIC % | 30.17 | |||||
ROC (Joel Greenblatt) % | 337.01 | |||||
ROCE % | 25.71 | |||||
Years of Profitability over Past 10-Year | 2 |
GF Value Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 11.16 | |||||
Forward PE Ratio | 9.65 | |||||
PE Ratio without NRI | 7.49 | |||||
Price-to-Owner-Earnings | 92.52 | |||||
PS Ratio | 1.05 | |||||
PB Ratio | 4.48 | |||||
Price-to-Free-Cash-Flow | 16.83 | |||||
Price-to-Operating-Cash-Flow | 8.77 | |||||
EV-to-EBIT | 6.97 | |||||
EV-to-EBITDA | 5.28 | |||||
EV-to-Revenue | 1.06 | |||||
EV-to-Forward-Revenue | 1.17 | |||||
EV-to-FCF | 17.45 | |||||
Earnings Yield (Greenblatt) % | 14.35 | |||||
FCF Yield % | 5.94 |